-
公开(公告)号：US12195464B2
公开(公告)日：2025-01-14
申请号：US17652076
申请日：2022-02-22
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor： Peng Li
IPC: C07D471/16
Abstract: The disclosure provides a new, stable, pharmaceutically acceptable bis-tosylate salt form of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′: 4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one: together with methods of making and using them, and pharmaceutical compositions comprising them.
-
公开(公告)号：US20240294545A1
公开(公告)日：2024-09-05
申请号：US18028960
申请日：2021-09-27
Inventor： Chuanwu Zhao , Zhenyu Wang , Chaozai Zhang , Fei Qi , Liqian Chen , Chunhua Jiang , Lixue Fan , Xiaoling Chai , Chunna Li , Yan Zhang
IPC: C07D498/16 , A61K31/4745 , A61K31/551 , A61K31/553 , A61K31/554 , A61K45/06 , A61P35/00 , C07D471/16 , C07D498/22 , C07D513/16 , C07D519/00
CPC classification number: C07D498/16 , A61K31/4745 , A61K31/551 , A61K31/553 , A61K31/554 , A61K45/06 , A61P35/00 , C07D471/16 , C07D498/22 , C07D513/16 , C07D519/00
Abstract: The present invention belongs to the technical field of medicines, and relates to a class of fused ring compound, and the preparation and use thereof. Test results show that the compounds can significantly inhibit the ATM kinase activity, have a good selectivity for the ATM target, and have the pharmaceutical use of treating cancer.
-
公开(公告)号：US20230339951A1
公开(公告)日：2023-10-26
申请号：US18327607
申请日：2023-06-01
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor： Peng LI , Qiang ZHANG , Robert DAVIS , Lawrence P. WENNOGLE
IPC: C07D471/14 , A61K47/38 , A61K9/48 , C07D471/16 , A61K9/50 , A61K47/34 , A61K31/4985
CPC classification number: C07D471/16 , A61K9/4825 , A61K9/4891 , A61K9/5031 , A61K31/4985 , A61K47/34 , A61K47/38 , C07D471/14
Abstract: The invention relates to pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) pathway and/or the dopamine D2 receptor pathway, and methods of treating conditions of the central nervous system therewith.
-
公开(公告)号：US20230009130A1
公开(公告)日：2023-01-12
申请号：US17818606
申请日：2022-08-09
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor： Peng LI , Qiang ZHANG
IPC: C07D471/16 , C07D519/00
Abstract: The present invention provides improved methods for the preparation of substituted heterocycle fused gamma-carbolines, intermediates useful in producing them and methods for producing such intermediates and such heterocycle fused gamma-carbolines.
-
公开(公告)号：US20220372035A1
公开(公告)日：2022-11-24
申请号：US17813473
申请日：2022-07-19
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor： Peng LI , Hailin ZHENG , Robert DAVIS , Sharon MATES , Kimberly VANOVER , Gretchen SNYDER
Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the μ-opioid receptor.
-
Patent Agency Ranking
公开(公告)号：US20220363682A1
公开(公告)日：2022-11-17
申请号：US17815843
申请日：2022-07-28
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor： Lawrence P. WENNOGLE , Peng LI , Edwin ARET
IPC: C07D471/16
Abstract: The disclosure provides new, stable, pharmaceutically acceptable hydrochloride salt forms of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H -pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.
-
公开(公告)号：US20220281867A1
公开(公告)日：2022-09-08
申请号：US17652076
申请日：2022-02-22
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor： Peng LI
IPC: C07D471/16
Abstract: The disclosure provides a new, stable, pharmaceutically acceptable bis-tosylate salt form of 1-(4-fluoro-phenyl)-4-((6bR, 10aS)-3-methyl-2,3,6b,9,10, 10a-hexahydro-1H,7H-pyrido [3′,4′:4,5]pyrrolo [1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.
-
公开(公告)号：US20220169650A1
公开(公告)日：2022-06-02
申请号：US17456106
申请日：2021-11-22
Applicant: ALIGOS THERAPEUTICS, INC.
IPC: C07D471/16 , A61K45/06 , A61K31/519 , A61K31/675 , A61P31/14
Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20220127268A1
公开(公告)日：2022-04-28
申请号：US17570502
申请日：2022-01-07
Applicant: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Inventor： Ariel MITTELMAN , Ido FUCHS , Sharona SHACHANTOV , Doron RUDIK , Rotem SELLA-EREZ
IPC: C07D471/16 , C07C309/30
Abstract: Disclosed are solid state forms of lumateperone ditosylate, uses thereof, and pharmaceutical compositions thereof.
-
公开(公告)号：US11311536B2
公开(公告)日：2022-04-26
申请号：US16221162
申请日：2018-12-14
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor： Peng Li
IPC: A61K31/4985 , A61K9/20 , A61K9/16 , A61K9/00 , A61K47/38 , A61P25/28 , A61P25/22 , A61P3/04 , A61P25/18 , A61P25/24 , A61P25/06 , A61K9/48 , C07D471/16 , A61K9/10
Abstract: The disclosure provides new, stable, pharmaceutically acceptable amorphous solid dispersions of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.
-
-
-
-
-
-
-
-
-
Search Results
472
records
(took 0.029 seconds)
